FDA grants accelerated approval to Nuvalent's Nelkarmi for previously treated ALK-positive lung cancer

Nuvalent's Nelkarmi has received FDA accelerated approval for previously treated ALK-positive advanced lung cancer, offering another targeted treatment option for patients whose disease has progressed after earlier therapies.
On 17 November 2026, the US Food and Drug Administration granted accelerated approval to Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer following specified prior ALK inhibitor treatment, with previous platinum chemotherapy additionally required for one eligible treatment-history group.
In the ALKOVE-1 trial, objective response rates were 49% among patients previously treated with alectinib and 32% in a more heavily pretreated cohort; the accelerated approval is based on tumour response and response duration rather than established overall-survival benefit, and continued authorisation may depend on confirmatory evidence.
Field | Content |
Company | Nuvalent |
Medicine | Nelkarmi (neladalkib) |
Regulatory Authority | US Food and Drug Administration |
Approval Date | 17 November 2026 |
Approval Type | Accelerated approval |
Therapeutic Area | Oncology |
Indication | Locally advanced or metastatic ALK-positive non-small cell lung cancer |
Molecular Target | ALK |
Eligible Patients | Adults meeting specified prior ALK inhibitor treatment requirements; platinum chemotherapy additionally required for one treatment-history group |
Treatment Setting | Previously treated advanced or metastatic disease |
Supporting Study | ALKOVE-1 |
Response Rate After Alectinib | 49% objective response rate |
Response Rate in Heavily Pretreated Cohort | 32% objective response rate |
Approval Evidence | Objective response rate and duration of response |
Regulatory Limitation | Overall-survival benefit has not been established by the evidence described |
Confirmatory Requirements | Continued accelerated approval may depend on verification of clinical benefit |
Primary Source | https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


Commenti